Chen Yu

Chen Yu currently serves as a board member for multiple pharmaceutical companies, including Pathalys Pharma, LB Pharma, ADARx Pharmaceuticals Inc., Alkeus Pharmaceuticals, Upstream Bio, Arbor Biotechnologies, and Artios Pharma Ltd, with tenures beginning from 2021 to 2024. Additionally, Chen is a founding managing partner at TCG X since January 2021. Past board memberships include Structure Therapeutics until its IPO in February 2023 and Tarsus until its IPO in August 2020. Chen Yu holds an MBA from Stanford University Graduate School of Business and a BA in Biology from Harvard University, supplemented by medical training at Stanford University School of Medicine.